EIM
MACK

Essex Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Essex Investment Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-3,686
Closed -$211K – 401
2014
Q2 		$211K Buy
+3,686
New +$187K 0.03% 331

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Essex Investment Management's MACK Position: Q3 2014 in Review

Essex Investment Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2014, closing a stake of 3,686 shares — an estimated $211K sold.

Essex Investment Management first reported a position in MACK in Q2 2014 and held it in 1 quarter. The position peaked at $211K in Q2 2014. 132 funds tracked by Wall St. Rank hold MACK as of Q3 2014.

  • Essex Investment Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Essex Investment Management sold 3,686 Merrimack Pharmaceuticals, Inc. shares in Q3 2014, an estimated $211K.
  • Essex Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 1 quarter.
  • Essex Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $211K in Q2 2014.
  • 132 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2014.

Based on Essex Investment Management's 13F filing for Q3 2014, filed 29 Oct 2014.